BDBM468111 (R)-N-(1-Acryloylpyrrolidin-3-yl)-5-(*S)-(6-(cyclopentyloxy)-4- methylpyridin-3-yl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8- triazaacenaphthylene-2-carboxamide;::US10800792, Example 776::US10822348, Example 776

SMILES Cc1cc(OC2CCCC2)ncc1-n1c2ccnc3sc(C(=O)N[C@@H]4CCN(C4)C(=O)C=C)c([nH]c1=O)c23

InChI Key InChIKey=XZPXQCYCCBBWEA-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 468111   

TargetTyrosine-protein kinase BTK(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM468111(US10800792, Example 776 | US10822348, Example 776 ...)
Affinity DataIC50: 7.94nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK [386-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM468111(US10800792, Example 776 | US10822348, Example 776 ...)
Affinity DataIC50: 7.94nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
Go to US Patent